专利检索 ap:("Bristol-Myers Squibb Company" OR "Janssen Pharmaceuticals, Inc.") AND inv:"Andrew Karl Dilger" 第 1 页

1.

发明申请
ANTIBODIES AND ANTIGEN BINDING PEPTIDES FOR FACTOR XIA INHIBITORS AND USES THEREOF 有权

公开(公告)号：US20220220220A1

公开(公告)日：2022-07-14

申请号：US17570649

申请日：2022-01-07

申请人： Bristol-Myers Squibb Company , Janssen Pharmaceuticals, Inc.

发明人： Joseph M. Luettgen , Lumelle Schneeweis , Ginger Chao Rakestraw , Christina Terragni , Andrew Karl Dilger , Jason Robert Pinckney , Steven Sheriff , Kevin Kish , Yongmi An , William R. Ewing , Stanley Richard Krystek, JR. , Aaron Paul Yamniuk

IPC分类号： C07K16/36 , C07K16/44 , A61P7/04 , G01N33/86 , G01N33/94

摘要： The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.

2.

发明授权
Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof 有权

公开(公告)号：US12065505B2

公开(公告)日：2024-08-20

申请号：US17570649

申请日：2022-01-07

申请人： Bristol-Myers Squibb Company , Janssen Pharmaceuticals, Inc.

发明人： Joseph M. Luettgen , Lumelle Schneeweis , Ginger Chao Rakestraw , Christina Terragni , Andrew Karl Dilger , Jason Robert Pinckney , Steven Sheriff , Kevin Kish , Yongmi An , William R. Ewing , Stanley Richard Krystek, Jr. , Aaron Paul Yamniuk

IPC分类号： C07K16/36 , A61K39/00 , A61P7/04 , C07K16/44 , G01N33/86 , G01N33/94

CPC分类号： C07K16/36 , A61P7/04 , C07K16/44 , G01N33/86 , G01N33/94 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/92

摘要： The present invention provides novel antigen binding peptides, such as an antibody or antibody fragment, that specifically bind to selective FXIa inhibitors and/or dual inhibitors of FXIa, and plasma kallikrein. The present invention further relates to methods of reducing the antithrombotic effect of FXIa inhibitors by administering to a subject a pharmaceutically effective dose of the antigen binding peptides provided herein. In addition, the present invention provides detection reagents and methods for detecting the level of the inhibitors of FXIa in a biological sample.